Oculis Holding AG (OCS) Other Non-Current Assets (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Other Non-Current Assets came in at $1.0 million in Q1 2026, up 79.9% year-on-year from $565023.3 in Q1 2025, and up 3.5% quarter-over-quarter from $982168.3 in Q4 2025.
Oculis Holding AG (OCS) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Oculis Holding AG's Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 79.9% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $1.0 million, a 79.9% increase from a year earlier, with the FY2025 full-year figure at $946810.9, up 74.99% from the prior year.
- Other Non-Current Assets rose to $1.0 million in Q1 2026 per OCS's latest filing, from $982168.3 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.0 million in Q1 2026 and bottomed at $76813.6 in Q4 2022.
- The 5-year median for Other Non-Current Assets is $196831.2 (2024), against an average of $411139.4.
- Across the five-year window, Other Non-Current Assets increased 25.66% in 2024 and surged 466.87% in 2025, its largest moves.
- Year by year, Other Non-Current Assets stood at $76813.6 in 2022, then jumped by 30.62% to $100334.5 in 2023, then surged by 441.55% to $543364.4 in 2024, then soared by 80.76% to $982168.3 in 2025, then increased by 3.5% to $1.0 million in 2026.
- Per Business Quant, the three latest OCS Other Non-Current Assets figures stand at $1.0 million (Q1 2026), $982168.3 (Q4 2025), and $665058.3 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 14.48 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 63.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 982,168.29 |
| Sep 30, 2025 | 665,058.26 |
| Jun 30, 2025 | 643,805.49 |
| Mar 31, 2025 | 565,023.27 |
| Dec 31, 2024 | 543,364.40 |
| Sep 30, 2024 | 183,518.95 |
| Jun 30, 2024 | 196,831.24 |
| Mar 31, 2024 | 99,674.36 |
| Dec 31, 2023 | 100,334.55 |
| Sep 30, 2023 | 146,047.68 |
| Jun 30, 2023 | 125,675.84 |
| Dec 31, 2022 | 76,813.62 |